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journal home page: www.elsevier .com/ locat e/ i j idTuberculosis today remains the world’s number one cause of death
from an infectious disease (WHO, 2018a). According to data from the
World Health Organization Global Tuberculosis Report (WHO, 2018a),
global efforts to control tuberculosis are not on target to achieve the
goals of the WHO Strategy to end the global tuberculosis epidemic by
2030 (WHO, 2015). In 2017, an estimated 10 millionpeople (5.8 million
men, 3.2 million women, and 1 million children) developed
tuberculosis and 4 million people with tuberculosis remained
undiagnosed and untreated. There were 558,000 new cases of
drug-resistantTB,82%ofwhichweremulti-drugresistanttuberculosis
(MDR-TB-resistance to isoniazid and rifampicin), and 8.5% has
extensively drug resistant TB (XDR-TB -MDR-TB plus resistance to
both a ﬂuoroquinolone and an injectable) (WHO, 2018a).
Each year, World TB Day is commemorated on March 24, the day
in 1882 when Professor Robert Koch ﬁrst announced his discovery
of Mycobacterium tuberculosis, the causative agent of tuberculosis
(TB). It’s a day when the world reﬂects on progress being made in
achieving global TB control, the obstacles and what more can be
done to facilitate global TB control activities. The theme for World
TB Day on 24 March 2019 will be ‘It’s TIME’ (STOP TB Partnership,
2019), and it has been kept simple and ﬂexible, so World TB Day
events can cover any aspect of work related to TB.
To commemorate World TB Day 2019, the International Journal of
Infectious Diseases thematic issue contains 15 articles written by a
distinguished global authorship covering a range of important
epidemiological, clinical, management, prevention, research and
funding issues. The articles provide a range of thought-provoking
viewpoints on established dogma, current controversies, highlight-
ing gaps and future challenges that need to be overcome to develop
and achieve optimal interventions required for global TB control.
These articles also illustrate vividly that ‘It’s Time’ for governments
and donors to keep the promises made in the political declaration at
the UNGA-HLM-TB and to increase the much-needed resources to
ﬁnd, diagnose and treat 40 million adults and children who will be
affected by TB by 2022, and to conduct research on new diagnostics,
treatments and vaccines required to achieve global TB control (Tiberi
S et al. 2018; Zumla & Petersen, 2018).
Pathogen M. tuberculosis versus host battleground
An estimated 1.7 billion people worldwide have latent M.
tuberculosis infection (LTBI) (Houben and Dodd, 2016). Of these, uphttps://doi.org/10.1016/j.ijid.2019.02.024
1201-9712/© 2019 The Authors. Published by Elsevier Ltd on behalf of International Soc
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).to 10% are at risk of re-activating into active TB during their
lifetime. Latent M. tuberculosis infection is deﬁned by the World
Health Organization (WHO) as ‘a state of persistent immune
response to M. tuberculosis antigens with no evidence of clinically
active TB disease’ (WHO, 2018b). The underlying host innate and
acquired immune mechanisms underlying the state of LTBI remain
undeﬁned. Progress in understanding these through recent
developments in understanding the granuloma as the host-
pathogen battleground is reviewed by Rao et al. (2019a).
Tuberculin skin test and screening for LTBI
All countries signed uptothe prioritycommitment in the political
declaration arising from the historic United Nations High Level
Meeting on TB held on September 28th 2018 (WHO, 2018c) for
providing preventive treatment to 30 million individuals with LTBI
by 2022. Screening for LTBI is also key toTB control and achieving the
EndTB Strategy goals (WHO, 2015). The available LTBI screening tests
include the interferon release assays (IGRAs) and the tuberculin skin
test (TST), all of which are not accurate and cannot distinguish LTBI
from active TB disease. Gualano et al. (2019) argue that TST is still a
useful tool because it is well known, widely used and cheap. Clinical
use of the TSTas opposed to IGRAs should be prioritized according to
availability of reagents, resources, national recommendations and
speciﬁc clinicalscenario. Clinical judgementremains fundamental in
selecting the LTBI tests and interpreting the results of IGRA/TST tests.
The ultimate test awaited is one that can more speciﬁcally
distinguish active TB from LTBI. The use of IGRAs has increased in
low TB endemic areas but TST will continue to be clinically useful in
low and high TB endemic areas, until more predictive tests become
available to allow for identiﬁcation of individuals at the highest risk
of progressing to developing active TB diseases.
LTBI and drug-resistant TB exposure
Thetreatmentof suspectedlatent multidrug resistant TB (MDR-TB)
is discussed by Moore et al. where they highlight important issues and
unknowns about the management of individuals who have been
exposed to infectious MDR-TB within the household. They vividly
illustrate the complexities of management with patient case histories
and the shortcomings of current recommendations by international
agencies, due to a lack ofan evidence base. Current guidelines from theiety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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cases for2 years but stop short of recommending treatment for all. The
viewpoint suggests that until the three ongoing randomised
controlled trials of preventive therapy (V-QUIN trial, TB CHAMP and
PHOENix trial) are completed, there will remain large knowledge gaps
about how individuals known to have been exposed to patients with
MDR-TB should be managed. In the interim, there exists an important
opportunity to systematicallygather large-scale observational data on
exposed contacts under surveillance.
E-DETECT TB—a new surveillance database
Surveillance of populations at risk is a key to identify latent TB
before it become active TB and the migration from high prevalence
countries to low prevalence countries is an opportunity to identify
people with latent TB as described in the paper by Ohd et al. (2019).
Overcoming considerable administrative, practical and legal
challenges, they describe development of a newly developed
European database E-DETECT TB on latent and active TB in
migrants arriving in Europe. E-DETECT TB has started inviting
other EU member countries to contribute data to the database. E-
DETECT TB aims to address the present lack of evidence concerning
coverage, impact and cost-effectiveness in migrant TB screening.
Through collaborative efforts, country-level screening is collated
by using agreed key variables in a joint database.
LTBI and risk of tuberculosis in transplant recipients
Tuberculosis is an important infectious disease cause of
morbidity and death in transplant recipients worldwide and this
is often a neglected clinical issue. Tuberculosis can also cause loss
of kidney allograft. Krishnamoorthy et al. (2019) highlight the
issues related to prevention, diagnosis and treatment of tubercu-
losis in renal transplant recipients. Most of the TB cases in renal
transplant recipients are due to re-activation of LTBI in the
recipient or from the donor kidney. TB can also occur due to
increased susceptibility to acquiring new M. tuberculosis infection
which rapidly progresses to miliary TB because of immunosup-
pressive therapy. They emphasise that all donors and recipients are
routinely screened for LTBI and active TB disease prior to transplant
(Krishnamoorthy et al., 2019), maintaining a high degree of clinical
awareness of the possibility of TB.
Non-communicable diseases and LTBI
The association between chronic non-communicable diseases
diabetes mellitus type 2, chronic kidney disease and rheumatoid
arthritis and LTBI has been a subject of much discussion and
debate. Any medical condition which impairs the immune system
will lead to an increase risk of LTBI developing into active TB.
Ugarte-Gil et al. (2019) review the increasing evidence that
people with non-communicable diseases constitute a high-risk
group for both acquiring LTBI and developing active TB. They
remind us that with the global pandemic of type 2 diabetes,
diabetes has become an important risk factor for developing
active TB disease. Although the potential pathophysiological and
immunological pathways between several noncommunicable
diseases and LTBI and/or active TB disease are better known,
further studies evaluating better screening tools for LTBI, safe
prophylaxis, and treatments for TB in this speciﬁc population are
much needed (Ugarte-Gil et al., 2019).
Treatment landscape for MDR/XDR-TB
The relentless spread of MDR-TB and the high mortality rates
are fuelled by intermittent access to drugs, signiﬁcant drugadverse effects and poor adherence to medication. Only about
55% of MDR-TB cases who receive treatment are successfully
treated. The most important issues in TB treatment are related to
what are the optimal regimens for MDR/XDR-TB, drug toxicity,
availability of drugs and patient adherence and follow-up.
Honeyborne et al. (2019) review the current the changing
treatment landscape for MDR/XDR-TB and discuss whether
results from current ongoing clinical trials will revolutionise
and inform a brave new world of MDR-XDR-TB treatment?
Newly-approved TB drugs such as bedaquiline and delamanid
provide new treatment options for MDR/XDR-TB and several
ongoing trials are described, which if successful, will reduce
treatment for MDR/XDR-TB to 6–9 months.
Regulating and deﬁning antibiotic resistance breakpoints
Using the famous saying of the philosopher George Santayana,
‘Those who cannot remember the past are condemned to repeat it’
Köser et al. (2019) remind us that despite the consensus that
antibiotic resistance represents a key driver for poor treatment
outcomes, the standards to deﬁne resistance that apply to all other
major bacterial pathogens have not been followed for traditional
anti-TB drugs. The classiﬁcation of M. tuberculosis as susceptible or
resistant to a drug depend on reliable laboratory support for the
clinician, no matter whether molecular or culture methods are
used. They highlight that six years after the approval of bedaquiline
and delamanid, neither Janssen or Otsuka have generated the
necessary data to deﬁne robust breakpoints to these agents. They
call upon EMA and FDA to ensure that history does not repeat itself
when they approve novel anti-TB agents. They also suggest that
since WHO effectively controls the market size for novel drugs, it
should adopt a more muscular approach to ensure that pure,
quality-controlled compounds are available immediately to all
laboratories wishing to implement phenotypic DST.
Gatekeeper Consilia for new TB drugs
MDR-TB is a growing challenge worldwide and 2 million cases of
MDR-TB are anticipated within the next two decades. One of the
potential causes of MDR-TB is iatrogenic and we risk losing our new
drugs through inexperience and repetition of basic errors of adding
single active drugs to failing regimens. Tiberi et al. (2019) justify the
formation of TB Consilia act asgatekeeperstothe new drugs, monitor
guideline adherence and mandate active drug safety monitoring. TB
consilia are now recommended by funding bodies, the WHO and
manufacturers of drugs available for compassionate use in the hope
thatthesedrugswillbeprotectedandwillcontinuetobeuseful inthe
future. They discuss Consilia, their origin and evolution and give
some examples of how they operate. The Consilia concept may
ensure that the advice of experts in TB management is available to
health care staff throughout a country and is seen as an important
guarantee that new TB drugs are used appropriately thus increasing
the argument that they should be made available for compassionate
use (Tiberi et al., 2019).
Clustering and spatial distribution of smear positive pulmonary
tuberculosis cases in China
The annual incidence of notiﬁed smear positive pulmonary TB
cases in China is 30 per 100 000 population. Mao et al. (2019)
investigated the spatio-temporal variations of 4,711,571 smear
positive pulmonary TB cases. The clustering and spatial distribu-
tion is discussed the gradual decrease in the number reported
smear-positive PTB case was because of intensive measures on TB
including implemented DOTS and national TB prevention and
control plans, improved case notiﬁcations, increased TB budget
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government dominance (Mao et al., 2019). The most likely spatio-
temporal cluster was detected in four periods and located areas in
the central region, covering the Hubei, Hunan, Jiangxi, Anhui, as
well as Guizhou and Guangdong. They conclude that their results
indicated that the capability and utility of the spatio-temporal
approach in epidemiology characteristics and suggested that the
high-risk periods and areas should be paid more attention for
monitoring and early warning.
Reducing mortality in Brazilian TB patients
A study from the State of Paraná, Brazil, from 2008 to 2015 of 944
deaths of adult TB patients showed that three quarters of deaths
occurred within 60 days of diagnosis. The authors highlight that the
prime problem is late diagnosis and adherence to treatment.
Adequate monitoring of comorbidities and multisectoral support
may prevent early and late death (Oliveira et al., 2019). They suggest
that communication between health services at the different levels
such as primary, secondary, laboratory and hospital is fundamental
to promote integrated care. The presence of comorbidities and
individual behaviours that cause vulnerabilities associated with
early death reinforces the need for more frequent contact between
patients and health professionals, individualised therapeutic regi-
mens and multisectoral support to ensure better adherence to
treatment and thus prevent death caused by TB.
Holistic family-centred multisectoral care for children with TB
TB affects children’s health and development in multiple ways,
directly through disease and its sequalae and indirectly through the
health and survival of their primary care givers according to Detjen
et al. (2019). Responses to reduce TB-related disease and death in
children therefore need to be family-centered and multi-sectoral,
addressing TB within the context of the broader determinants of
health. They state that Primary health care (PHC) as envisaged by the
Alma Ata and Astana declarations calls for health services to be
improved through the lens of equity and community vulnerability,
highlighting that implementing integrated packages of interven-
tions speciﬁcally at the community and primary health facility level
will avert 77% of preventable maternal, newborn and child deaths.
Renewed focus on holistic PHC will enhance countries’ efforts to
reach maternal, newborn and child health targets contained in the
Sustainable Development Goals (SDGs).
Prevention, BCG efﬁcacy and new boosters
Whilst there is consensus that BCG vaccination of infants provides
protection against disseminated TB disease, TB meningitis and death,
the efﬁcacy of BCG in preventing adult pulmonary TB is not as widely
accepted by the global TB community. de Gijsel and von Reyn. (2019)
review the protective efﬁcacy of BCG vaccination against pulmonary
TB in adults. They summarize an increasing body of good quality
evidence to conclude that BCG provides up to 80% efﬁcacy against
pulmonary TB for 10 years and 50% efﬁcacy for 50 years. Their
conclusion is based on both prospective trials that now include
recently updated follow-up data, as well as new retrospective reviews
fromNorwayand the UK. These studies refute the myth that BCG is not
effectiveagainstpulmonaryTB.Theysuggestthatdevelopmentofnew
priming vaccines to replace BCG and new boosters to extend efﬁcacy
should be based on this current body of data.
Better use of combination of existing tools
The search for new tools to end the TB epidemic has also
focussed attention on the use of existing tools and ensuringmaximal beneﬁt. Gosce et al. (2019) in their viewpoint discuss the
hypothesis of BCG vaccination following latent TB treatment and
its potential impact across different settings. They point out several
studies which have shown the importance of implementing
different preventive strategies alongside treatment of TB disease,
including BCG vaccination and treatment of LTBI. Large-scale
population level LTBI treatment is not currently part of WHO
guidelines which recommend LTBI treatment only to high-risk
populations. Moreover, BCG is known to be highly efﬁcacious if
given to individuals who are not already infected with M.
tuberculosis. Thus, a combined LTBI treatment followed by BCG
vaccination could be tried in trials in countries with a high
prevalence of drug-resistant TB (Gosce et al., 2019).
Future therapies—precision medicine and MDR-TB
Multidrug-resistant TB (MDR-TB) is a major threat to global
health. In 2017, only 55% of patients with MDR-TB who received
WHO recommended treatment were cured (WHO, 2018a). Many
patients with MDR-TB patients who recover after receiving WHO-
approved MDR-TB treatment regimens continue to suffer from
functional disability due to lung damage. Thus, conventional TB
drug therapy needs to be complemented with host-directed
therapies (HDTs) to reduce tissue damage and improve functional
treatment outcomes. Rao et al. (2019b) viewpoint focusses on the
expanding pipeline of new and repurposed drugs and cell-based
therapies which have potential for use as host-directed therapies
for adjunct treatment of MDR-TB. They also review recent data on
biomarkers, immune cells, circulating effector molecules and
genetics which could be utilised for developing personalised HDTs
in light of experiences in cancer therapy. New concepts are always
difﬁcult for funding agencies and reviewers to understand and take
forward but with time these will see the light of day and make an
important contribution to ‘holistic’ management of MDR/XDR-TB.
Conclusions
Fulﬁlling the WHO EndTB strategy goals and achieving global
TB control remains a daunting and seemingly unachievable task
at the current slow pace of progress. The papers in this World TB
Day 2019 theme series present examples of the numerous
challenges that face global control efforts, as well as potential
solutions. The historic UN-General Assembly High-Level Meeting
on TB held in New York in September 2018 (Petersen et al., 2017)
focused global attention on the world’s deadliest infectious
disease and generated high expectations of a major ‘step-up’ in
political will to bring the devastating global TB epidemic under
control. World TB Day 2019 events worldwide should ensure that
political and donor commitments made at the UNGA-HLM-TB are
delivered in a timely fashion, including increased funding for
research and innovation for new and improved diagnostic,
treatment and prevention tools. Meanwhile tuberculosis health
services globally should receive adequate funding to reach out to
all communities and high-risk groups, proactively diagnose, and
treat all adults and children with tuberculosis in all of its clinical
forms, and make bedaquiline and delamanid available universally
for effective treatment of MDR-TB.
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